Core differences in the GLP-1 diet among different populations:
Diabetics emphasize "sugar stabilization + hypoglycemia prevention", and weight loss people emphasize "calorie control + nutritional balance", but they all need to be based on high-protein, high-fiber, and low-glycemic index foods, with regular meals and moderate exercise.
Diabetic patients (especially GLP-1 drugs)

1. Priority goal: stabilize blood sugar and avoid hypoglycemia
   Staple foods are mainly whole grains and miscellaneous legumes, such as brown rice, oats, quinoa, chickpeas, etc., and avoid refined carbohydrates such as white rice, white bread, and white noodles.
   Pair each meal with plenty of vegetables and high-quality protein (fish, eggs, soy products, lean meat) to delay the rise in blood sugar.
   Avoid high-sugar foods such as sugary drinks, desserts, and fruit juices, choose low-GI varieties (such as apples, pears, strawberries), and control portion sizes.
   If insulin or sulfonylureas are used, the dosage should be adjusted under the guidance of a doctor to avoid hypoglycemia caused by GLP-1 drugs + dietary control.
2. Meal rhythm and monitoring
   Eat three meals regularly, add meals if necessary (such as a small serving of nuts, yogurt), and avoid prolonged fasting.
   Monitor blood sugar regularly and record changes in diet and blood sugar to facilitate doctors to adjust medication and diet plans.
   People who are simply losing weight (without diabetes)
3. Priority goal: calorie control + nutritional balance
   On the basis of the GLP-1 diet, the total calories should be appropriately reduced, but excessive dieting should not be done to avoid muscle loss and metabolic decline.
   Ensure that each meal contains protein (such as chicken breast, fish, tofu, eggs) and plenty of vegetables to increase satiety.
   Control fats and refined carbohydrates (fried foods, desserts, sugary drinks), but you don't have to cut out staple foods altogether, opt for whole grains and potatoes.
   Avoid "extreme diets" (such as not eating staple foods at all, eating only fruits, etc.) to avoid nutritional imbalance.
4. Exercise and lifestyle habits
   Combining aerobic exercise (brisk walking, swimming, cycling) and strength training helps maintain muscle mass and basal metabolism.
   Ensuring adequate sleep and hydration reduces stress, aiding in hormone balance and weight management.
5. Common principles of the two types of people
   Food choices: Mainly high-protein, high-fiber, low-glycemic index foods, such as vegetables, legumes, whole grains, lean meats, fish, eggs, dairy products.
   Meal order: Eat vegetables/protein first, then staple foods, which can help improve satiety and blood sugar stability.
   Processed foods: Reduce or avoid high-sugar, high-fat, and highly processed foods (such as crackers, potato chips, sausages, instant noodles).
   Individualized adjustments:
   If you have comorbidities such as kidney disease, high uric acid, and high blood pressure, you need to adjust your protein and salt intake under the guidance of a doctor or dietitian.
   If you are using GLP-1 drugs, be sure to follow the doctor's advice and regularly review liver and kidney function, blood lipids and other indicators.
   Special Reminder:
   The above is a general dietary recommendation, and the specific plan needs to be combined with personal health conditions, medication, weight goals and other factors, and an individualized plan is formulated by a doctor or dietitian, and it is not recommended to use GLP-1 drugs or extreme diets for a long time.

In addition to diet, regular exercise, adequate sleep, stress management, smoking cessation and alcohol restriction can all help increase GLP-1 levels and improve blood sugar and weight control.
1. Exercise: Aerobic + strength training has the best effect
Aerobic exercise: brisk walking, jogging, swimming, cycling, etc., at least 150 minutes of moderate intensity or 75 minutes of high intensity per week, can significantly increase GLP-1 secretion and improve insulin sensitivity.
Strength training: 2–3 times a week, such as squats, push-ups, dumbbell lifts, etc., to increase muscle mass and help stabilize blood sugar and GLP-1 levels in the long term.
Walking after meals: Walking for 10–15 minutes 30 minutes after meals can promote GLP-1 release and help control blood sugar after meals.
2. Sleep: Ensure 7-9 hours of high-quality sleep
Lack of sleep or poor quality can reduce GLP-1 secretion and increase ghrelin levels, leading to increased appetite and a desire to eat high-sugar and high-fat foods.
It is recommended to set a regular schedule, avoid blue light devices before going to bed, and keep the bedroom dark and quiet, which can help improve sleep quality.
3. Stress management: reduce the interference of cortisol on GLP-1
Long-term stress can raise cortisol, inhibit GLP-1 secretion, increase abdominal fat accumulation and blood sugar fluctuations.
Relax through meditation, deep breathing, yoga, listening to music, etc., and set aside 10–15 minutes of stress reduction time each day.
4. Quit smoking and limit alcohol to avoid interfering with hormone balance
Quit smoking: Smoking lowers GLP-1 levels, increasing insulin resistance and cardiovascular risk.
Alcohol limit: Excessive alcohol can interfere with blood sugar and GLP-1 secretion, and it is recommended that no more than 2 standard glasses per day for men and 1 standard glass (1 standard glass ≈ 14g of pure alcohol) for women.
5. Comprehensive suggestions
Combining exercise, sleep, stress reduction, and healthy eating can be far more effective than a single change.
If you are using GLP-1 drugs, it is recommended to adjust your lifestyle under the guidance of a doctor to avoid risks such as hypoglycemia.
The above is general health advice, if you have underlying diseases such as diabetes and obesity, please refer to the specific plan of clinicians and dietitians.

GLP-1 friendly food refers to a type of food that can promote GLP-1 secretion in the body, help control sugar, and increase satiety. It mainly includes high protein, high fiber, healthy fat, and calcium rich foods, while avoiding high sugar, high-fat, and overly processed foods.
1. Recommended food categories
High-quality protein
Lean meats, fish and shrimp, eggs, dairy products, soy products, legumes and nuts, etc., can significantly promote GLP-1 release and enhance satiety.
High-fiber vegetables
Asparagus, broccoli, artichokes, celery, etc., eating vegetables first before eating staple foods can help increase postprandial GLP-1 levels and stabilize blood sugar.
Healthy fats
Deep-sea fish such as olive oil, avocados, nuts, chia seeds, flaxseeds, and salmon can increase GLP-1 secretion while improving blood lipids and metabolism.
Dairy
Milk, yogurt, cheese, etc. are rich in calcium, and studies have shown that a high-calcium breakfast can significantly increase GLP-1 levels and prolong satiety.
Whole grains and legumes
Oats, rye, lentils, chickpeas, etc., rich in dietary fiber and resistant starch, contribute to gut health and support GLP-1 secretion.
Fermented foods
Fermented foods such as miso, kimchi, and natto help improve intestinal flora and indirectly support the secretion of GLP-1-related hormones.
2. Foods that should be reduced or avoided
High-sugar foods such as sugary drinks, candies, and biscuits can quickly raise blood sugar and are not conducive to GLP-1 secretion.
Fried foods, pastries, processed meat products, etc. contain trans fats and refined carbohydrates, which can interfere with GLP-1 secretion and blood sugar stability.
Excessive alcohol can disrupt blood sugar and GLP-1 levels, and it is recommended to limit intake.
3. Eating tips
Adjust the eating order: Eat vegetables and protein first, and then staple foods, which can help enhance GLP-1 secretion and blood sugar control.
Eat regular meals and eat small and frequent meals: Avoid prolonged fasting to help stabilize blood sugar and hormone levels.
Chew Enough: Eating whole, chewy foods and increasing the number of chews can increase GLP-1 levels.
4. Special reminder
If you are using GLP-1 drugs (such as semaglutide, tirpotide, etc.), it is recommended to develop an individualized diet plan under the guidance of a doctor or dietitian, taking into account nutrient density and calorie control, and avoid muscle loss and malnutrition.
The above advice is general nutritional guidance, if you have underlying diseases such as diabetes and obesity, please refer to the specific recommendations of clinicians and dietitians.

Calcitonin (CT) is a 32 peptide hormone secreted by parafollicular cells (C cells) in the thyroid gland. It was first discovered and demonstrated by Hirsh to regulate calcium phosphorus metabolism. At present, calcitonin has shown good efficacy in the treatment of osteoporosis, Paget's disease, hypercalcemia, hyperparathyroidism, osteoarthritis, and bone healing. However, during the use of calcitonin, it has also been found that the drug has common drawbacks as protein and peptide drugs, such as immunogenicity and short half-life. There have been clinical reports that calcitonin can cause allergic reactions. In addition, due to the half-life of calcitonin in the human body being 70-90 minutes and its rapid metabolism, it needs to be administered daily or every other day, which also brings difficulties and pain to patients in treatment.
In this study, a polyethylene glycol-modified calcitonin was provided, characterized by a long chain of polyethylene glycol derivatives attached to the amino group of calcitonin by covalent bonds, and the group directly linked to the amino group of calcitonin was methylene or carbonyl. Using salmon calcitonin, the amino acid composition sequence of salmon calcitonin is:
H-Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-【Lys】-Leu-Ser-Gln-Glu-Leu-His-【Lys】-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-【Pro】-NH2( Two Cys can form disulfide bonds; The molecular formula is C145H240N44O48S2; The molecular weight is 3432.
Example 1 mPEG-SPA-5000 modifies the synthesis of salmon calcitonin
Selection of reaction temperature:
Take 2ml of 1.0mg/ml salmon calcitonin solution, add 2ml of phosphate buffer solution to make the pH value of the solution 7.0, then add 15mg of mPEG-SPA-5000 solid, dissolve, mix well, take 0.8ml each and place it in 4 stoppered test tubes, and then place them at 4 ℃, 10 ℃, 25 ℃, and 37 ℃ for 30 minutes. Add 5mg of glycine to terminate the reaction. Compare the modification rate of single polyethylene glycol modified salmon calcitonin (a salmon calcitonin molecule with one polyethylene glycol chain attached, hereinafter referred to as polyethylene glycol modified salmon calcitonin) and determine the modification conditions.
The results showed that polyethylene glycol-modified salmon calcitonin could be obtained at these temperatures, and the modification rate was the highest at 25°C.
Selection of reaction time:
Take 2ml of 1.0mg/ml salmon calcitonin solution, add 2ml of phosphate buffer to make the pH value of the solution 7.0, then add 15mg of mPEG-SPA-5000 solid, dissolve, mix well, take 0.7ml of each and put it in 4 corked test tubes, and then react at 25°C for 5, 15, 30, 60 and 120 min, then add 5mg glycine to stop the reaction. Compare the modification rate and determine the modification conditions.
The results showed that pegylated salmon calcitonin could be obtained under these conditions, and the modification rate did not increase significantly after 30 minutes.
Molar ratio of mPEG-SPA-5000 to salmon calcitonin:
Take 8ml of 1.0mg/ml salmon calcitonin solution, add 8ml of phosphate buffer to make the pH value of the solution 7.0, take 3.0ml of each and put it in 5 corked test tubes, and then add 2.2, 4.4, 6.6, 11.0 and 22.0mg mPEG-SPA-5000 (equivalent to the molar ratio of salmon calcitonin and mPEG-SPA-5000 is 1∶1, 1∶2, 1∶3, 1∶5, 1∶10, respectively), dissolve, mix, and mix. The reaction is terminated after 30 minutes. Compare the modification rate and determine the modification conditions. The results showed that the polyethylene glycol-modified salmon calcitonin could be obtained under these conditions, and the modification rate reached the highest when the molar ratio of mPEG-SPA-5000 and salmon calcitonin was 3.
Example 2 Isolation, purification and identification of polyethylene glycol-modified salmon calcitonin
Take 1.0mg/ml of salmon calcitonin solution, add 10ml of phosphate buffer to make the pH value of the solution 7.0, then add 44mg of mPEG-SPA-5000 solid, dissolve, mix well, react at 25°C for 30min, and add 25mg glycine to stop the reaction. The above reaction solution was taken and replaced with an ultrafiltration membrane with an intercepted molecular weight of 1000, and the acetate-sodium acetate buffer with a pH of 4.0 was replaced and concentrated to 5ml, and separated on the column. The chromatographic conditions are as follows:
Chromatography medium: SOURCE30S
Column volume: 5ml
Flow rate: 3.0ml/m
in Column equilibration: Equilibrate 5 times the column volume with 0.01mol/L, pH 4.0 sodium acetate (starting buffer)
Loading volume: 5ml
Elution: The unadsorbed part is eluted with a starting buffer of 3 times the column volume, and then a gradient is used to elute the starting buffer, 1.0mol/LNaCl buffer, and the percentage of 1.0mol/LNaCl buffer volume is from 0~100%, and the column volume is eluted 20 times the column volume. Collection: 3.0ml/tube was followed up with RP-HPLC, combined with polyethylene glycol-modified salmon calcitonin, and purified by reversed-phase column chromatography. The chromatographic conditions for reversed-phase column chromatography are as follows: Chromatography medium: Reversed-phase silica gel (C18, 40 μm)
Column volume: 10ml
Flow rate: 3.0ml/m
in Column equilibration: 10 times the column volume equilibrated with 0.5%
acetic acid solution: 10ml
Elution: The unadsorbed part is eluted with 0.5% acetic acid solution with 5 times the column volume, and then the gradient solution is composed of 0.5% acetic acid solution and 0.5% acetate ethanol solution, and 0.5% acetate ethanol solution is used to elute 30 times the column volume. Collection: 3.0ml/tube was followed up with RP-HPLC and combined with pegylated salmon calcitonin.
RP-HPLC analysis showed that the purity of the obtained polyethylene glycol-modified salmon calcitonin was more than 98%, as shown in Figure 1, which had a high purity.
The molecular weight of polyethylene glycol-modified salmon calcitonin was measured to be 8187.31 by MALDI-TOF-MS, as shown in Figure 2.
The molecular weight of salmon calcitonin is 3432, the molecular weight difference between the two is about 5000, and there is a series of peaks near 8187.31 (M+1 peak), which has the typical structural characteristics of polyethylene glycol, which confirms that the polyethylene glycol-modified salmon calcitonin obtained in embodiment 2 is a single modification product.
Example 3 Comparison of salmon calcitonin and polyethylene glycol-modified salmon calcitonin (prepared by the method of embodiment 2) to reduce blood calcimon in rats
Referring to the potency determination method of calcitonin in Appendix XIIO of Part II of the Chinese Pharmacopoeia in 2005, 90 Wistar female rats weighing 200±15g were selected and fasted for 16 hours before the test, freely drank distilled water, and were randomly divided into 3 groups, with 30 blank, salmon calcitonin and polyethylene glycol-modified salmon calcitonin groups. The dose of salmon calcitonin and pegylated glycol-modified salmon calcitonin was 0.05 μg/kg (calculated by the amount of salmon calcitonin in pegylated glycol-modified salmon calcitonin), and the volume was 0.4 ml/100 g. Before administration and 1, 2, 4, 8, and 12 hours after administration, 5 animals were taken from each group, blood was collected from the ocular venous plexus, and the blood calcium value in the samples was determined by o-cresol phthalein complex. The average blood calcium value of the blank group at each time point is subtracted from the average blood calcium value of the administration group, and the difference between the two is used to compare the average blood calcium value of the blank group with the average blood calcium value of the upper blank group, that is, the blood calcium level can be reduced. The results showed that the polyethylene glycol-modified salmon calcitonin not only did not decrease, but also increased significantly, and the level of blood calcium reduced by 1 times at the same dose was also significantly extended, from 4 hours to 8 hours before modification.
Example 4 Study of the immunogenicity of polyethylene glycol-modified salmon calcitonin (prepared by the method of embodiment 2) on experimental animals
Rabbits were used as experimental animals to prepare antiserum, and formaldehyde-treated salmon calcitonin and polyethylene glycol-modified salmon calcitonin were used as antigens, at a dose of 0.5mg/kg/time, once a week, for a total of 5 times. Salmon calcitonin and pegylated salmon calcitonin were used as antigens, and their respective antiserum titers were determined by two-way immunodiffusion assay, and the results showed that the antiserum titers of salmon calcitonin group were 1∶32. The antiserum titer of the salmon calcitonin group modified by polyethylene glycol could not be measured. Salmon calcitonin and polyethylene glycol-modified salmon calcitonin were used as antigens, and then the antiserum of the salmon calcitonin group was used as the primary antibody, and then horseradish peroxidase (HRP)-labeled sheep anti-rabbit IgG was used as the secondary antibody, and their respective immunogenicity was determined by enzyme-linked immunosorbent assay (ELISA), and the results were as follows: salmon calcitonin group was positive, and pegylated salmon calcitonin group was negative. The above results show that compared with salmon calcitonin, the immunogenicity of pegylated salmon calcitonin modified by polyethylene glycol is significantly reduced, which is more conducive to its use as a therapeutic drug.
Example 5 mPEG-SPA-2000, mPEG-SPA-10000, mPEG-SPA-20000, mPEG-SPA-30000 mPEG-SPA-60000 replace mPEG-SPA-50000 in embodiment 1, and use the methods of embodiments 1 and 2 to obtain polyethylene glycol-modified salmon calcitonin, and perform experiments such as embodiments 3 and 4 to obtain similar results.
Example 6 mPEG-SBA-2000, mPEG-SBA-5000, mPEG-SBA-10000, mPEG-SBA-20000, mPEG-SBA-30000 or mPEG-SBA-60000 instead of mPEG-SPA-5000 in embodiment 1, using the methods of embodiments 1 and 2 to obtain polyethylene glycol-modified salmon calcitonin, and conducting experiments such as embodiments 3 and 4 to obtain similar results.
Example 7 Selection of reaction temperature of salmon calcitonin modified with methoxy polyethylene glycol propionaldehyde 5000 (mPEG-ALD-5000): take 2ml of 1.0mg/ml salmon calcitonin solution, add 2ml of phosphate buffer to make the pH value of the solution 5.0, then add 30mg of mPEG-ALD-5000 solid, dissolve, mix well, and then add 0.029ml of 1mol/L sodium cyanobohydride, Take 0.8ml of each and place it in 4 plugged test tubes, then put it at 4°C, 25°C, 37°C and 50°C for 16h, and then add 5mg glycine to stop the reaction. Compare the modification rate and determine the modification conditions. The results showed that polyethylene glycol-modified salmon calcitonin could be obtained at these temperatures, and the modification rate was the highest at 37°C.
Selection of reaction time: take 2ml of 1.0mg/ml salmon calcitonin solution, add 2ml of phosphate buffer to make the pH value of the solution 5.0, then add 30mg of mPEG-ALD-5000 solid, dissolve, mix well, add 0.029ml of 1mol/L sodium cyanoboron hydride, take 0.7ml of each and put it in 5 corked test tubes, and then react at 37°C for 0.5, 1.0, 8.0, 16.0, 24.0h, and then add 5mg glycine to terminate the reaction. Compare the modification rate and determine the modification conditions. The results showed that salmon calcitonin modified by polyethylene glycol could be obtained under these conditions, and the modification rate did not increase significantly after 16 hours.
Selection of molar ratio of mPEG-ALD-5000 to salmon calcitonin: take 8ml of 1.0mg/ml salmon calcitonin solution, add 8ml of phosphate buffer to make the pH value of the solution 5.0, take 3ml of each and put it in 5 corked test tubes, and then add 2.2, 6.6, 11.0, 22.0 and 33.0mg of mPEG-ALD-5000 (equivalent to the molar ratio of calcitonin to mPEG-ALD-5000 in 1∶1~1∶15), Dissolve, mix well, then add 0.022ml of 1mol/L sodium cyanobohydride for 16.0h, and then add 5mg glycine to stop the reaction. Compare the modification rate and determine the modification conditions. The results showed that the modification rate of salmon calcitonin modified with pegylated glycol was the highest when the molar ratio of mPEG-ALD-5000 to calcitonin was 10, and the modification rate of mPEG-ALD-5000 was not significantly increased.
Example 8 Separation, purification and identification of polyethylene glycol modified salmon calcitonin (aldehyde modification) Take 10ml of salmon calcitonin solution at 1.0mg/ml, add 10ml of phosphate buffer to make the pH value of the solution 5.0, then add 150mg of mPEG-ALD-5000 solid, dissolve, mix well, add 0.145ml of 1mol/L sodium cyanoborohydride, react at 37°C for 16h, and then add 50mg of glycine solid to stop the reaction. Then, according to the method in embodiment 2, the separation, purification and identification of polyethylene glycol-modified calcitonin are carried out. RP-HPLC analysis showed that the purity of the obtained polyethylene glycol-modified salmon calcitonin was more than 98%, which was relatively high. MALDI-TOF-MS analysis showed that its molecular weight was 8124.21, which was a monomodified polyethylene glycol-modified salmon calcitonin.
Example 9 Study on the characteristics of polyethylene glycol modified salmon calcitonin (aldehyde modification) The test and immunogenicity study of mPEG-ALD-5000 modified salmon calcitonin to reduce blood calcimon in rats were carried out according to the method in embodiment 3~4, and the results not only did not decrease the titer, but also significantly increased, the action time was significantly prolonged, and the immunogenicity was reduced.
Example 10 replacing mPEG-ALD-5000 in embodiment 7 with mPEG-ALD-2000, mPEG-ALD-10000, mPEG-ALD-20000, mPEG-ALD-30000 or mPEG-ALD-60000, using the methods of embodiments 7 and 8 to obtain polyethylene glycol-modified salmon calcitonin, and conducting experiments as in embodiment 9 to obtain similar results.
Example 11 mPEG-bALD-2000, mPEG-bALD-5000, mPEG-bALD-10000, mPEG-bALD-20000, mPEG-bALD-30000 or methoxy polyethylene glycol butyraldehyde 60000 (mPEG-ButyrALD-60000) are used instead of mPEG-ALD-5000 in embodiment 7, and polyethylene glycol modified salmon calcitonin is obtained by the methods of embodiments 7 and 8 , and conduct experiments such as the embodiment 9 to obtain similar results.
We are a professional researcher and manufacturer of pharmaceutical polymer materials, providing gram, kilogram, tonnGMP and GMP pharmaceutical PEG, PLA, PLGA, and provide complete quality research reports. We are committed to escorting the development of your medical devices and welcoming more patients.
Email address: haoran.tse@gmail.com
Tel: +8618575536586

Melanotan I, also known as Afamelanotide, is a linear polypeptide composed of 13 amino acids that is bound to play a greater role in drug research. The main English names of melanotan I are Melanotan-1 and Afamelanotide, as an artificial synthetic analogue of α-melanotropin (α-MSH), melanotan I can be used to treat photosensitive diseases caused by erythropoietic protoporphyria, and most melanotan I products are only labeled for scientific research and are not used in the human body for the time being. In traditional solid-phase synthesis, the choice of resin will have a great impact on the coupling rate and final purity of the product.

Basic information
Chinese name: melanotan I
English name: Melanotan-1
CAS Number: 75921-69-6
Sequence: Ac-SYS{Nle}EH{D-Phe}RWGKPV-NH2
Formula: C78H111N21O19
Molecular weight: 1646.88
Preparation Approach

1. Preparation of Fmoc-Val-amino resin
   Step 1: Weigh 11.11g (5mmol) of Ramage Amide AM resin resin with a substitution of 0.45mmol/g and add it to the solid-phase reactor, add DCM swelling resin for 30 minutes, drain it, wash it three times with DMF, add a volume ratio of 20% hexahydropyridine DMF solution, react for 5 minutes, add 20% hexahydropyridine DMF solution to react for 10 minutes, wash the DMF in the middle once, and drain it at the end of the reaction. DMF wash 3 times.
   Step 2: Dissolve 5.09g of Fmoc-Val-OH, 2.02g of HOBT (1-hydroxybenzotriazole), and 2.32ml of DIC (N,N'-diisopropylcarbodiimide) in DMF at 0°C, and add it to the reaction column for room temperature reaction for 1 hour after complete dissolution.
   
2. Preparation of melanotan I fully protective resin peptideS
   tep 1: Add 20% hexahydropyridine DMF solution to the above Fmoc-Val-amino resin, react for 5 minutes, add 20% hexahydropyridine DMF solution again for 10 minutes, wash the middle DMF once, drain it at the end of the reaction, and wash the DMF 3 times.
   Step 2: 5.06g of Fmoc-Pro-OH, 2.02g of HOBT (1-hydroxybenzotriazole), and 2.32ml of DIC (N,N'-diisopropylcarbodiaimide) will be dissolved in DMF at 0°C, and after complete dissolution, add to the reaction column for room temperature reaction for 1 hour.
   Step 3: According to the method of step 2, according to the sequence of melanotane I, conjugate each amino acid in turn, react to Ac-Ser(tBu)-OH After completion, DMF washes three times, DCM washes three times, methanol washes three times, and drains 23.89g of melanotane I full protection resin peptide.
3. Preparation of melanotan I crude peptide
   Put 23.89g of melanotan I fully protective resin peptide into a round-bottom flask, slowly add 250ml of the configured lysate at 0°C (the volume ratio of the reagent formula used in the lysate is TFA: benzosulfide: phenol: triisopropylsilane: water = 82.5:7.5:5:3:2) and stir slowly, Reaction at low temperature for 0.5 hours, reaction at room temperature for 2 hours, filter to obtain lysate, slowly add the lysate to 2L of anhydrous ice ether and stir, filter and separate crude peptides, wash the ice ether 3 times, and obtain 8.55g of melanotan I crude peptides.
   
4. Preparation of melanotan I high-quality peptidesS
   tep 1: Dissolve the crude peptide of melanotan I in 100ml of purified water and filter it with a 0.45μm filter membrane to obtain a crude peptide solution.
   Step2. Purification of melanotan I crude peptide using high performance liquid chromatography instrument: Through the DAC-HB50 dynamic axial compression column, mobile phase A is an aqueous solution of 0.05% trifluoroacetic acid and B is a solution of 0.05% acetonitrile trifluoroacetate with a mass concentration of 0.05%, and the peptide solution of the target peak is collected by gradient elution.
   Step 3: After high-performance liquid phase purification, 180ml of melanotane I trifluoroacetic acid liquid with a purity greater than 99% is obtained, and 50ml of liquid is obtained after spin steaming and concentration.
   Step 4: The column was equilibrated with deionized water and loaded, the sample volume was 50ml, the purity was greater than 99% melanotane I trifluoroacetic acid liquid, eluted in 2% acetic acid aqueous solution system for 50min, the collected target product was rotated and concentrated to 80ml, pre-lyophilized and lyophilized, and finally 5.33g of melanotan I fine peptide was obtained, with a yield of 32.33%.